What is the level of liabilities of ImmuCell this year?
ImmuCell has a debt balance of 18.82 M USD this year.
ImmuCell Liabilities 2024
ImmuCell Liabilities
18.82 M USD
Ticker
ICCC
ISIN
US4525253062
WKN
885825
In 2024, ImmuCell's total liabilities amounted to 18.82 M USD, a 29.94% difference from the 14.48 M USD total liabilities in the previous year.
ImmuCell Aktienanalyse
What does ImmuCell do?
ImmuCell Corp is an American company that specializes in the development and marketing of veterinary products for the ruminant industry. It was originally founded in the late 1970s under the name PrioGene and initially focused on the development of diagnostics for tuberculosis and brucellosis in cattle. In the 1990s, the company changed its name to ImmuCell and shifted its focus to the development of products to support animal health. ImmuCell's business model is centered around the development, manufacturing, and sale of products to improve animal health. They offer a wide range of veterinary products, including immunoassays, vaccines, antibiotics, and complementary feeds. The company aims to improve animal health with minimal impact on the environment and works closely with veterinarians and industry experts. They have divisions dedicated to diagnostics, vaccines, and antibiotics, and their products can help identify and prevent diseases in livestock. Notable products include the LBC mastitis diagnostic and the Immu-PRIME spray for preventing umbilical infections in newborn calves. ImmuCell has established itself as a leading innovator in the animal health industry and has conducted clinical studies on the efficacy of their HO-VAX product. In conclusion, ImmuCell focuses on developing and marketing products to support animal health, with a commitment to improving the well-being of livestock. ImmuCell ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing ImmuCell's Liabilities
ImmuCell's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating ImmuCell's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing ImmuCell's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
ImmuCell's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in ImmuCell’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about ImmuCell stock
What were the liabilities of ImmuCell compared to the previous year?
The liabilities of ImmuCell have increased by 29.94% increased compared to the previous year.
What are the consequences of high debt for investors of ImmuCell?
High liabilities can pose a risk for investors of ImmuCell, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in ImmuCell?
Low liabilities mean that ImmuCell has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of ImmuCell affect the company?
An increase in liabilities of ImmuCell can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of ImmuCell affect the company?
A decrease in the liabilities of ImmuCell can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of ImmuCell?
Some factors that can influence the liabilities of ImmuCell include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of ImmuCell so important for investors?
The liabilities of ImmuCell are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can ImmuCell take to modify the liabilities?
To change its liabilities, ImmuCell can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does ImmuCell pay?
Over the past 12 months, ImmuCell paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ImmuCell is expected to pay a dividend of 0 USD.
What is the dividend yield of ImmuCell?
The current dividend yield of ImmuCell is .
When does ImmuCell pay dividends?
ImmuCell pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of ImmuCell?
ImmuCell paid dividends every year for the past 0 years.
What is the dividend of ImmuCell?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is ImmuCell located?
ImmuCell is assigned to the 'Health' sector.
Wann musste ich die Aktien von ImmuCell kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of ImmuCell from 7/31/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/31/2024.
When did ImmuCell pay the last dividend?
The last dividend was paid out on 7/31/2024.
What was the dividend of ImmuCell in the year 2023?
In the year 2023, ImmuCell distributed 0 USD as dividends.
In which currency does ImmuCell pay out the dividend?
The dividends of ImmuCell are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von ImmuCell
Our stock analysis for ImmuCell Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ImmuCell Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
